Cleveland Clinic

Latest from Cleveland Clinic

How Do Education, Social Support Affect PAP Adherence in Patients With OSA?

May 07, 2021

The group-based Sleep Apnea Management clinic at Cleveland Clinic's Sleep Disorders Center increased criteria-met adherence to positive airway pressure (PAP) therapy by 20% in patients with obstructive sleep apnea (OSA).

The Role of SGLT-2 Inhibitors in Heart Failure: A Roundtable Discussion

September 18, 2020

The American Journal of Managed Care® recently hosted a Peer Exchange that featured discussion among a panel of expert cardiologists and managed care decision makers regarding how cardiovascular outcome trial results are impacting the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure and how these drugs are shaping heart failure outcomes for patients. Panelists were Nihar R. Desai, MD, MPH, assistant professor of medicine in the cardiovascular medicine section of the Yale School of Medicine and investigator in the Center for Outcomes Research and Evaluation in New Haven, Connecticut; Jaime Murillo, MD, national senior director of cardiology at UnitedHealthcare in Fort Lauderdale, Florida; and Steven Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic in Cleveland, Ohio. The moderator was Neil B. Minkoff, MD, chief medical officer of Coeus Consulting Group in Sudbury, Massachusetts.

Dr Abby Statler: African American Patients With AML Exhibit Higher Kidney Test Abnormalities

February 26, 2020

When we looked at the pre-treatment creatinine data, we found that African Americans were more likely to have abnormal results and white patients were more likely to have normal results–these differences were statistically significant, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.

Dr Abby Statler Speaks on Eligibility Criteria Exclusions for MDS Clinical Trials

February 21, 2020

Our outcomes suggest that eligibility criteria for patients with MDS relevant to liver function, renal function, and comorbidities may be relaxed, especially for those who have minor renal function abnormalities who have shown to have similar clinical outcomes to those without such abnormalities, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.

Dr Abby Statler Discusses Restrictive Criteria Excluding Minority Patients From AML Trials

January 03, 2020

In research presented at the 61st American Society of Hematology Annual Meeting and Exposition, Abby Statler, PhD, MPH, MA, research associate, Cleveland Clinic, and her colleagues found that African Americans with acute myeloid leukemia (AML) may be excluded from clinical trials due to renal dysfunction, despite it having no impact on AML outcomes.